Integrated mPD-L1 and metabolic analysis identifies new prognostic subgroups in lung cancers with wild-type EGFR

Clin Transl Med. 2021 Dec;11(12):e612. doi: 10.1002/ctm2.612.

Authors

Guosheng Wang^{1

2}, Weilei Hu³, Yundi Chen², Yuan Wan², Qiang Li¹

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
² The Pq Laboratory of Micro/Nano BiomeDx, Department of Biomedical Engineering, Binghamton University-SUNY, Binghamton, New York, USA.
³ Institute of Translational Medicine, Zhejiang University, Hangzhou, China.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
B7-H1 Antigen / analysis
B7-H1 Antigen / metabolism*
ErbB Receptors / analysis
ErbB Receptors / genetics
Female
Humans
Lung Neoplasms / complications*
Lung Neoplasms / diagnosis
Lung Neoplasms / physiopathology
Male
Middle Aged
Prognosis*
RNA, Messenger / analysis

Substances

B7-H1 Antigen
CD274 protein, human
RNA, Messenger
EGFR protein, human
ErbB Receptors

Grants and funding